# EDGAR Filing Document

**Accession Number:** 0001958777
**File Stem:** 0000000000-26-002965
**Filing Date:** 2026-3
**Character Count:** 2470
**Document Hash:** d88fd1e395229c1ad4240d1498a077b5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-26-002965.hdr.sgml**: 20260501

**ACCESSION NUMBER**: 0000000000-26-002965

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260324

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** FibroBiologics, Inc.
- **CENTRAL INDEX KEY:** 0001958777
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 863329066
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 377-09156

**BUSINESS ADDRESS:**
- **STREET 1:** 9350 KIRBY DRIVE
- **STREET 2:** SUITE 300
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77054
- **BUSINESS PHONE:** 281-671-5150

**MAIL ADDRESS:**
- **STREET 1:** 9350 KIRBY DRIVE
- **STREET 2:** SUITE 300
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77054

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** FibroBiologics Inc.
- **DATE OF NAME CHANGE:** 20221216
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001493152-26-011889

## Text-Extract

```

                                                            March 24, 2026

Pete O   Heeron
Chief Executive Officer
FibroBiologics, Inc.
455 E. Medical Center Blvd.
Suite 300
Houston, TX 77598

       Re: FibroBiologics, Inc.
           Draft Registration Statement on Form S-1
           Submitted March 20, 2026
           CIK No. 0001958777
Dear Pete O   Heeron:

       This is to advise you that we do not intend to review your registration
statement.

        We request that you publicly file your registration statement and
non-public draft
submission on EDGAR at least two business days prior to the requested effective
date and time.
Please refer to Rules 460 and 461 regarding requests for acceleration. We
remind you that the
company and its management are responsible for the accuracy and adequacy of
their disclosures,
notwithstanding any review, comments, action or absence of action by the staff.

       Please contact Daniel Crawford at 202-551-7767 with any questions.

                                                            Sincerely,

                                                            Division of
Corporation Finance
                                                            Office of Life
Sciences
cc:    Barrett DiPaolo, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._